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Objectives. To examine the extent and complexity of the morbidity burden in 85-year-olds; identify patterns withinmultimorbidity;
and explore associations with medication and healthcare use. Participants. 710 men and women; mean (SD) age 85.5 (0.4)
years. Methods. Data on 20 chronic conditions (diseases and geriatric conditions) ascertained from general practice records and
participant assessment. Cluster analysis within the multimorbid sample identified subgroups sharing morbidity profiles. Clusters
were compared on medication and healthcare use. Results. 92.7% (658/710) of participants had multimorbidity; median number of
conditions: 4 (IQR 3–6). Cluster analysis (multimorbid sample) identified five subgroups sharing similar morbidity profiles; 60.0%
(395/658) of participants belonged to one of two highmorbidity clusters, with only 4.9% (32/658) in the healthiest cluster.Healthcare
usewas high, with polypharmacy (≥5medications) in 69.8% (459/658). Between-cluster differences were found inmedication count
(𝑝 = 0.0001); hospital admissions (𝑝 = 0.022); and general practitioner (𝑝 = 0.034) and practice nurse consultations (𝑝 = 0.011).
Morbidity load was related to medication burden and use of some, but not all, healthcare services. Conclusions. The majority of 85-
year-olds had extensive and complex morbidity. Elaborating participant clusters sharing similar morbidity profiles will help inform
future healthcare provision and the identification of common underlying biological mechanisms.
1. Introduction
The concept of multimorbidity, the cooccurrence of two or
more chronic diseases in an individual [1], is attracting
increasing research and clinical interest (the related term
“comorbidity” is reserved for morbidity cooccurring in rela-
tion to a specific index disease [2]). Prevalence estimates for
multimorbidity range from 20 to 30% in “all age” popula-
tions and are as high as 55–98% in older populations [3]. The
cooccurrence of multiple diseases is associated with num-
erous adverse outcomes including disability, poor quality of
life, high healthcare use, and mortality [3, 4]. The provision
of effective and cost-effective care for people with multi-
morbidity presents a major challenge for healthcare systems
worldwide and is the subject of on-going debate [5–8]. In the
setting of multiple diseases, current approaches to chronic
disease management—based largely on the single disease
paradigm—can result in complex, fragmented, costly, and
potentially ineffective (or even injurious) care [9, 10].
Most multimorbidity research to date has focused on
measures based on a simple disease count [11], and there is
limited data on how and why particular conditions cooccur
and the specific combinations or patterns found. Improved
understanding of such patterns would inform the develop-
ment of better healthcare for patients with multimorbid-
ity and facilitate the identification of common underlying
biological mechanisms thereby potentially leading to novel
preventive and therapeutic measures [12].
People aged 85 years and over comprise the most rapidly
expanding age group in most parts of the world [13]. Whilst
multimorbidity is the norm in the very old [14, 15], there is
little detailed information on the morbidity profiles found
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in this age group. In this paper we examine the extent
and complexity of the morbidity burden in a population-
based sample of 85-year-olds (using the concepts of comor-
bidity and multimorbidity), identify patterns of morbidity,
and explore associations between morbidity profiles and
medication and healthcare use. To study morbidity within
a population requires comprehensive data on a representa-
tive group, which in the case of very old people is rarely
available given the inherent difficulty in working with this
potentially frail and vulnerable group. We used data from
the Newcastle 85+ Study, a population-based cohort study
capturing detailed information on the health of a large,
representative samplewhowere all aged 85 at baseline [16, 17].
Considerable effort was invested to secure inclusion of the
notably hard-to-reach groups, particularly those living in care
homes or with dementia [18]. A novelty of our approach
is the use of cluster analysis to identify distinct subgroups
of participants with similar combinations of conditions.
Furthermore, we included not only chronic diseases but also
geriatric syndromes and impairments. Such conditions are
as prevalent as chronic diseases in older people and have a
marked effect on quality of life, disability, institutionalisation,
healthcare use [19], and quality of care [20].However, they fall
outside the disease-focused medical model and have seldom
been included in multimorbidity measures.
2. Materials and Methods
2.1. Study Population. Full details of the Newcastle 85+ Study
have been reported [16–18]. In brief, members of the 1921
birth cohort living inNewcastle uponTyne orNorthTyneside
(North East England) were recruited at around age 85 using
general practice patient lists as the sampling frame. People
living in institutions and those with cognitive impairment
were included. Recruitment and baseline assessment took
place over a 17-month period in 2006-2007.
2.2. Study Protocol. Comprehensive measures of health were
collected at baseline across multiple clinical, biological, and
psychosocial domains. A health assessment—comprising
questionnaires, measurements, function tests, and a fasting
blood sample—was carried out in the participant’s usual
residence by a research nurse. General practice medical
records were reviewed for diagnosed diseases, prescribed
medication, and use of general practice services. In the
UK, patients are registered with a single general practice
which acts as a gatekeeper to secondary care and receives
details of all hospital admissions and outpatient attendances.
The review of general practice records included hospital
correspondence to ensure that all recorded disease diagnoses
were extracted, irrespective of where and when the diagnosis
was made.
2.3. Diseases and Geriatric Syndromes/Impairments Exam-
ined. Fifteen chronic diseases and five geriatric syndromes or
impairments (hereafter termed “geriatric conditions”) were
selected for investigation. The selection criteria included
known impact on morbidity, mortality, and/or healthcare
use; availability in the baseline Newcastle 85+ Study dataset;
prevalence greater than 3% at study baseline; and less than
10% missing values. Table 1 lists the 20 conditions examined,
togetherwith data sources and ascertainment criteria [21–25].
A systematic review by Diederichs et al. [26] recommended
the inclusion of 11 core conditions in any multimorbidity
measure, of which we included 10. We were unable to include
depression due to the high proportion (15%) of participants
with missing data for the depression measure used (15 item
Geriatric Depression Scale, GDS-15 [27]); this was mainly
because the GDS cannot be used in people with severe cog-
nitive impairment. We included the majority of the chronic
conditions prioritised by the UKNHSQuality andOutcomes
Framework for General Practice [28].
2.4. Medication. Data on prescribed medication was
extracted from the general practice records; all participant
medication prescribed for use in themonth prior to the health
assessment was recorded. A count ofmedications was created
after first excluding items such as seasonal vaccinations, diag-
nostic/monitoring agents, wound-management products,
and catheter/stoma products.
2.5. Use of Healthcare Services. Data on all consultations with
general practitioners and general practice employed nurses
(other community nurses were not included) was obtained
from the general practice records; a timeframe of 12 months
prior to the health assessment was used. Only contacts with
the participant’s registered general practice were recorded;
contactswith externally provided “out of hours” general prac-
tice services were excluded. Data on overnight hospital
admissions and contacts with outpatient and “Accident and
Emergency” services and “Day Hospital” and other interme-
diate care services was obtained by questionnaire (admin-
istered by the research nurse as part of the health assess-
ment). A timeframe of three months was used for outpatient
and “Accident and Emergency” services and 12 months for
overnight hospital admissions and intermediate care services.
2.6. Other Measures. Data on disability level was obtained by
nurse-administered questionnaire. A disability score (maxi-
mum 17) was calculated from the total number of activities
of daily living performed with difficulty or requiring an
aid/appliance or personal help [17].
2.7. Ethical Approval. The research complied with the
requirements of the Declaration of Helsinki. Ethical approval
was obtained from the Newcastle and North Tyneside 1
Research Ethics Committee (reference number 06/Q0905/2).
Written informed consent was obtained from participants;
where people lacked capacity to consent, for example, because
of cognitive impairment, a formal written opinionwas sought
from a relative or carer as previously reported [18].
2.8. Statistical Analysis. We first compared the sample with
complete data on all 20 conditions (analytic sample) to the
sample without complete data. Mann-Whitney 𝑈 tests were
used for nonnormally distributed continuous variables and
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Table 1: 20 diseases and geriatric conditions examined; data sources and ascertainment criteria.
Diseases (15)
Disease Data source Criteria
Hypertension General practice (GP)records Documented diagnosis of hypertension regardless of date.
Ischaemic heart disease
GP records and health
assessment (HA)
electrocardiogram
(ECG)
Documented diagnosis of angina or myocardial infarction or coronary artery
bypass grafts or coronary angioplasty or coronary stent regardless of date.
Participants without a preexisting diagnosis could be additionally assigned on the
basis of Minnesota codes [21] commencing 1-1 or 5-1 on 12 lead ECG conducted as
part of the health assessment.
Heart failure GP records Documented diagnosis of heart failure regardless of date.
Atrial fibrillation or
flutter HA ECG
Minnesota codes 8-3-1 or 8-3-2 on 12 lead ECG conducted as part of the health
assessment.
Cerebrovascular disease GP records Documented diagnosis of stroke or transient ischaemic attack or carotidendarterectomy regardless of date.
Peripheral vascular
disease GP records Documented diagnosis of peripheral vascular disease regardless of date.
Osteoarthritis GP records Documented diagnosis of osteoarthritis or cervical spondylosis or lumbarspondylosis regardless of date.
Inflammatory arthritis GP records Documented diagnosis of rheumatoid arthritis or psoriatic arthropathy orankylosing spondylitis regardless of date.
Osteoporosis GP records Documented diagnosis of osteoporosis regardless of date.
Chronic obstructive
pulmonary disease GP records
Documented diagnosis of chronic obstructive pulmonary disease (COPD)
regardless of date.
Asthma GP records Documented diagnosis of asthma excluding childhood asthma and excludingasthma in conjunction with COPD.
Thyroid disease GP records Documented diagnosis of hypothyroidism or hyperthyroidism regardless of date.
Diabetes mellitus GP records Documented diagnosis of diabetes mellitus regardless of date.
Cancer within previous 5
years GP records
Documented diagnosis of cancer diagnosed within previous 5 years excluding
nonmelanoma skin cancer.
Renal impairment HA serum creatinine
Estimated glomerular filtration rate of less than 45mL/min/1.73m2 calculated using
the Chronic Kidney Disease Epidemiology Collaboration equation [22] using
serum creatinine measured as part of the health assessment. This cut point
identifies Stages 3B, 4, and 5 Chronic Kidney Disease [23].
Geriatric conditions (5)
Geriatric condition Data source Criteria
Urinary incontinence HA questionnaire Moderate, severe, or profound incontinence (classified on basis of frequency ofepisodes and volume of urine leakage [24]) or catheterised for previous 12 months.
Falls HA questionnaire Two or more falls in previous 12 months.
Visual impairment HA questionnaire Self-reported difficulty recognizing a friend across the road or reading ordinarynewsprint, with aids if worn.
Hearing impairment HA questionnaire Self-reported difficulty hearing someone taking in a quiet room or following aconversation with background noise, with aids if worn.
Cognitive impairment HA cognitive test Standardised minimental state examination score [25] of 21 or lower.
ordinal variables (disability score, education), and 𝜒2 tests for
categorical variables (sex, place of residence, and prevalence
of individual conditions). Sex differences in the prevalence of
individual conditions and in multimorbidity were examined
by 𝜒2 tests and sex differences in the total number of
conditions by Mann-Whitney 𝑈 tests. Cluster analysis was
used in the sample withmultimorbidity (𝑁 = 658) to identify
distinct subgroups of participants with similar combinations
of conditions.We first computed a dissimilaritymatrix, based
on Jaccard’s similarity coefficient, on participants’ morbidity
profiles, and then performed an agglomerative hierarchical
cluster analysis [29] using the Calinski/Harabasz index to
identify the optimal number of clusters. To characterise
between-cluster differences in morbidity profiles, we com-
pared the prevalence of each condition within a specific
cluster to that in the total sample with multimorbidity.
We defined “higher than average prevalence” as a ratio of
prevalence in the cluster to prevalence in the total sample of
1.2 : 1 or higher and “lower than average prevalence” as a ratio
of 0.8 : 1 or lower. Clusters were compared by 𝜒2 tests for sex
distribution, place of residence, and healthcare variables (any
use) and by Kruskal-Wallis tests for number of medications
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and healthcare variables (number of contacts/length of hospi-
tal stay). Analyses were performed using STATA version 12.0.
3. Results
3.1. Sample Selection. Details of sample selection for the
Newcastle 85+ Study have been reported [17] (and see the
Appendix; see Supplementary Material available online at
http://dx.doi.org/10.1155/2016/8745670).The recruited cohort
was sociodemographically representative of the local popula-
tion and of England and Wales, including the proportion in
care homes [17].The present analysis required data from both
the health assessment and review of general practice records
which was available for 845 participants, 58.2% (845/1453)
of those eligible to participate. Complete data on all 20
conditions was available for 710 of these participants (84.0%)
who formed the sample for the principal analyses (Appendix,
Supplementary Figure 1). Missing data arose from noncom-
pletion of questionnaires, electrocardiograms or blood tests.
Comparison of the groups with and without complete data
showed that those with missing data were more likely to
be female, to be resident in an institution, to have a higher
prevalence of osteoporosis, urinary incontinence, and cog-
nitive impairment, and to be more disabled than those with
complete data (Appendix, Supplementary Table 1).
3.2. Sample Characteristics. Of the 710 participantswith com-
plete data on all 20 conditions, themean (standard deviation)
age was 85.5 (0.4) years, 59.9% (425/710) were women and
99.6% (707/710) were of white ethnicity, reflecting the norm
for a UK population of this age (Table 2). The majority
(80.7%, 573/710) were living in standard (nonsupported)
housing, with 13.4% (95/710) in sheltered accommodation
and 5.9% (42/710) in an institution (all care homes). Of those
not living in an institution, 60.6% (404/667) were living
alone.
3.3. Prevalence of 20 Diseases and Geriatric Conditions.
Hypertension (57.8%, 410/710), osteoarthritis (57.0%, 405/
710), and ischaemic heart disease (36.1%, 256/710) were the
most prevalent diseases. Hearing impairment (60.4%, 429/
710), visual impairment (36.2%, 257/710), and urinary incon-
tinence (31.3%, 222/710) were the most prevalent geriatric
conditions (Table 2). Women had a significantly higher prev-
alence of osteoarthritis, osteoporosis, thyroid disease, and
urinary incontinence than men, whilst men had a higher
prevalence of atrial fibrillation/flutter and hearing impair-
ment (Appendix, Supplementary Table 2).
3.4. Comorbidity for Each of the 20 Diseases and Geriatric
Conditions. Figure 1 shows the prevalence of each of the 20
conditions with and without comorbidity, that is, the cooc-
currence of at least one other condition. Supplementary Table
3 (Appendix) shows, for each index condition, the prop-
ortion of cases with comorbidity together with the median
number of cooccurring conditions (for cases with at least one
cooccurring condition). We present the data both including
Table 2: Sample characteristics: 710 participants with complete data
on all 20 conditions.
Age, mean (SD) years 85.5 (0.4)
Female, % (𝑛) 59.9 (425)
White ethnicity, % (𝑛) 99.6 (707)
Living arrangements, % (𝑛)
Standard (nonsupported) housing 80.7 (573)
Sheltered housing 13.4 (95)
Institution 5.9 (42)
Years in full-time education, % (𝑛)
0–9 64.7 (458)
10-11 22.7 (161)
12+ 12.6 (89)
Diseases, % (𝑛)
Hypertension 57.8 (410)
Ischaemic heart disease 36.1 (256)
Heart failure 11.1 (79)
Atrial fibrillation or flutter 13.5 (96)
Cerebrovascular disease 21.1 (150)
Peripheral vascular disease 7.3 (52)
Osteoarthritis 57.0 (405)
Inflammatory arthritis 3.8 (27)
Osteoporosis 12.1 (86)
Chronic obstructive pulmonary disease 16.5 (117)
Asthma 4.1 (29)
Diabetes mellitus 13.5 (96)
Thyroid disease 14.8 (105)
Cancer within 5 years 6.2 (44)
Renal impairment 23.8 (169)
Geriatric conditions, % (𝑛)
Urinary incontinence 31.3 (222)
Falls 17.2 (122)
Visual impairment 36.2 (257)
Hearing impairment 60.4 (429)
Cognitive impairment 6.9 (49)
Disability score∗, median (IQR) 3 (1–6)
∗Total number of activities of daily living performed with difficulty or
requiring an aid/appliance or personal help [17].
and excluding geriatric conditions in the definition of cooc-
curring condition. Individual diseases and geriatric condi-
tions very rarely occurred in isolation. When geriatric con-
ditions were included as cooccurring conditions, over 96%
of cases of any index condition had at least one other cooc-
curring condition. The median (interquartile range, IQR)
number of cooccurring conditions ranged from 4 (3–5) for
hypertension, osteoarthritis, visual impairment, and hearing
impairment up to 6 (4–7) for heart failure. Excluding geriatric
conditions from the definition of cooccurring condition
generally had little effect on the proportion of disease cases
with comorbidity; the median (IQR) number of cooccurring
diseases ranged from 2 (2–4) for hypertension to 4 (3–5) for
heart failure and cancer (within five years).
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Figure 1: Prevalence of 20 diseases and geriatric conditions, with comorbidity (grey) and without comorbidity (black), in complete case
sample (𝑁 = 710).
3.5. Total Count of Diseases and Geriatric Conditions. The
median total number of conditions (diseases and geriatric
conditions) per participant was 4 (IQR, 3–6) and this was
higher in women (median 5, IQR 3–6) than men (median
4, IQR 3–6); 𝑝 value = 0.01. The median number of diseases
was 3 (IQR 2–4) and for geriatric conditions it was 1 (IQR 1-
2). Less than 1% (6/710) of participants had none of the 20
conditions and 6.5% (46/710) had only one condition, whilst
8.9% (63/710) had 8 or more conditions. The prevalence of
multimorbidity (two or more conditions) was 92.7% (658/
710) and was slightly, but not significantly, higher in women
(93.6%, 398/425) thanmen (91.2%, 260/285); 𝑝 value = 0.225.
3.6. Clusters of Participants with Similar Morbidity Profiles.
The 𝐹-statistic implied that the optimal number of clusters
lays between four and six, and subjective review suggested
that a five-cluster solutionwould yield groups ofmost clinical
relevance. The five clusters varied in prevalence within the
multimorbid sample; sex distribution; morbidity profile and
the mix found between diseases and geriatric conditions;
and use of healthcare services and prescribed medication.
Table 3 provides summary details of the cluster groups,
ordered and labelled alphabetically by cluster prevalence.
Table 4 lists condition prevalence by cluster, highlighting
those conditions occurring at higher and lower than average
prevalence (bold text = higher, ratio of prevalence in cluster to
prevalence in total sample with multimorbidity ≥1.2 : 1; italic
text = lower, ratio ≤0.8 : 1). Figure 2 shows the prevalence of
the 20 conditions within each of the five clusters and in the
total sample with multimorbidity.
The most common clusters—A (32.1% of multimorbid
sample, 211/658) and B (28.0%, 184/658)—were both charac-
terised by very high morbidity (10 conditions occurring at
higher than average prevalence). The pattern in Cluster A
was disease-based, whilst Cluster B had a mix of diseases and
geriatric conditions. In Cluster A, 10 diseases (hypertension,
heart failure, atrial fibrillation/flutter, cerebrovascular dis-
ease, peripheral vascular disease, renal impairment, diabetes,
asthma, thyroid disease, and cancer) occurred at higher than
average prevalence, whilst most of the geriatric conditions
occurred at lower than average prevalence. In contrast, in
Cluster B five diseases occurred at higher than average preva-
lence (atrial fibrillation/flutter, cerebrovascular disease, dia-
betes, inflammatory arthritis, and thyroid disease), together
with all five geriatric conditions. Clusters C (22.6% of sam-
ple, 149/658) and D (12.5%, 82/658) were characterised by
intermediate morbidity; four and six conditions, respectively,
occurred at higher than average prevalence, comprising a
mix of diseases and geriatric conditions. Cluster E (4.9%
of sample, 32/658), the least common group, appeared to
be the healthiest cluster; whilst five conditions occurred at
higher than average prevalence (mix of diseases and geriatric
conditions), 14 of the 20 conditions occurred at zero or
low prevalence. Higher than average prevalence was found
for three diseases (ischaemic heart disease, inflammatory
arthritis, and osteoporosis) and one geriatric condition (hear-
ing impairment) in Cluster C; three diseases (osteoarthritis,
chronic obstructive pulmonary disease, and asthma) and
three geriatric conditions (urinary incontinence, falls, and
cognitive impairment) in Cluster D; and two diseases (atrial
fibrillation/flutter and chronic obstructive airways disease)
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Figure 2: Prevalence of 20 diseases and geriatric conditions in each cluster group, and in total sample with multimorbidity.
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Table 4: Prevalence (%) of 20 conditions in each cluster and in total sample withmultimorbidity. Conditions occurring at higher than average
prevalence∗ are shown in bold text; those occurring at lower than average prevalence∗ are shown in italic text.
Cluster A Cluster B Cluster C Cluster D Cluster E Total multimorbid sample
𝑛 = 211 𝑛 = 184 𝑛 = 149 𝑛 = 82 𝑛 = 32 𝑛 = 658
Diseases
Hypertension 73.0 56.5 62.4 54.9 0.0 60.2
Ischaemic heart disease 42.2 40.2 54.4 9.8 6.3 38.6
Heart failure 26.1 6.5 6.7 1.2 3.1 12.0
Atrial fibrillation or flutter 18.0 18.5 8.7 2.4 21.9 14.3
Cerebrovascular disease 39.3 30.4 2.0 0.0 18.8 22.5
Peripheral vascular disease 12.3 7.6 7.4 0.0 3.1 7.9
Osteoarthritis 56.4 66.9 63.1 74.4 0.0 60.3
Inflammatory arthritis 3.3 4.9 6.0 2.4 0.0 4.1
Osteoporosis 10.9 11.4 18.1 14.6 6.3 12.9
Chronic obstructive pulmonary disease 15.2 17.9 8.7 26.8 46.9 17.5
Asthma 5.2 3.3 3.4 6.1 3.1 4.3
Thyroid disease 24.2 20.1 4.7 8.5 6.3 15.8
Diabetes mellitus 22.3 21.2 4.0 3.7 3.1 14.6
Cancer within 5 years 9.5 6.5 7.4 1.2 0.0 6.7
Renal impairment 58.3 16.3 6.7 6.1 3.1 25.7
Geriatric conditions
Urinary incontinence 15.6 79.4 6.0 41.5 0.0 33.7
Visual impairment 21.3 56.0 40.9 25.6 84.4 39.1
Hearing impairment 55.0 76.6 81.2 13.4 87.5 63.4
Falls 9.0 28.3 17.5 29.3 0.0 18.4
Cognitive impairment 3.3 9.8 3.4 19.5 9.4 7.5
∗Higher than average prevalence of a condition defined as a ratio of prevalence in cluster to prevalence in total sample with multimorbidity ≥1.2 : 1. Lower than
average prevalence of a condition defined as a ratio of prevalence in cluster to prevalence in total sample with multimorbidity ≤0.8 : 1.
and three geriatric conditions (visual impairment, hearing
impairment, and cognitive impairment) in Cluster E. Four
conditions—hypertension, osteoarthritis, hearing impair-
ment, and visual impairment—occurred at high prevalence
in at least four of the five clusters.
The total number of conditions amongst cluster group
members reflected the cluster morbidity profile; Clusters A
and B had the highest total number of conditions (medians
of five and six, resp.) with Clusters C, D, and E having lower
numbers (medians of four, three, and three, resp.). There
was a significant difference in sex distribution between the
clusters (𝑝 value = 0.002). Overall, women comprised 60.5%
(398/658) of the total sample with multimorbidity, whereas
Cluster E had equal numbers of men and women and in
Cluster D the proportion of women was 75.6% (62/82). Only
6.4% (42/658) of participantswithmultimorbiditywere living
in an institution (all in care homes); the prevalence was
somewhat higher in Clusters B (9.8%, 18/184) and D (9.8%
8/82), 𝑝 value = 0.056, which may reflect the high proportion
with cognitive impairment in those clusters.
3.7. Medication and Healthcare Use. Participants with mul-
timorbidity were high consumers of healthcare, particularly
primary care (Table 5). Prescribed medication burden was
also high, with polypharmacy (five or more medications)
in 69.8% (459/658) of participants and 17.3% (114/658) pre-
scribed 10 or more medications. Between-cluster differences
were found in the number of medications (𝑝 value = 0.0001);
overnight hospital admissions (proportion admitted at least
once in previous 12 months, 𝑝 value = 0.022); general
practitioner consultations (proportion consulting at least
once in previous 12 months, 𝑝-value = 0.034); and general
practice nurse consultations (proportion consulting at least
once in previous 12 months, 𝑝 value = 0.011 plus number
of consultations for those consulting, 𝑝 value = 0.009). For
medication, hospital admissions, and general practice nurse
consultations, the level of use generally reflected cluster
morbidity load with higher use found in Clusters A and
B. In those with at least one hospital admission, there was
some suggestion of a higher total length of stay in Cluster B,
although the difference did not reach statistical significance
(𝑝 value = 0.058). Whilst there were cluster differences in
the proportion consulting their general practitioner at least
once during the previous 12 months, the high percentage
found in all clusters (87.8–97.3%) makes it difficult to deter-
mine whether this variation is of clinical significance. The
number of general practitioner contacts, amongst those who
consulted, was similar across clusters. Given the difference in
sex distribution between clusters and that we have previously
found sex differences in general practice nurse consultations
in this cohort (women having lower levels of use than
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men) [17], we repeated the analysis of general practice nurse
consultations adjusting for sex. Between-cluster differences
remained in both the proportion consulting (𝑝 value = 0.026)
and the number of consultations (𝑝 value < 0.001).
4. Discussion
We have reported novel data detailing the extensive and
complex morbidity burden found in a UK population-based
cohort of 85-year-olds and the relationship between morbid-
ity profiles and medication and healthcare use. Novel aspects
of our approach include the use of cluster analysis to identify
distinct subgroups of participants with similar combinations
of conditions and the inclusion of geriatric syndromes and
impairments in addition to diseases. We found that chronic
diseases and geriatric conditions were both common in the
very old and that individual conditions very rarely occurred
in isolation. Multimorbidity was almost universal and the
average number of conditions was high. Cluster analysis
identified five distinct subgroups of participants with similar
patterns of morbidity. The two most prevalent clusters,
accounting for 60% of the sample, showed very high levels of
morbidity; one was predominantly disease-based, whilst the
other comprised a mix of diseases and geriatric conditions.
The healthiest profile accounted for only 5% of the sample
and, even in this “healthy” cluster, participants still had an
average of three conditions. Participants withmultimorbidity
were high consumers of healthcare, particularly primary care,
and prescribed medication burden was high with polyphar-
macy (five or more prescribed medications) found in almost
70%.
It should be noted that cluster analysis is an exploratory
technique and different clustering algorithms can produce
varying results [30]. However, our findings of disease com-
binations which mirror known groupings and the between-
cluster differences in healthcare use provide evidence of the
validity of our approach. Cluster A included five interlinked
“circulatory” diseases (hypertension, heart failure, atrial fib-
rillation/flutter, cerebrovascular disease, and peripheral vas-
cular disease) and three diseases associated with circulatory
disease (diabetes, thyroid disease, and renal impairment).
Cluster A also included cancer which could be linked to
circulatory diseases through the common risk factor of smok-
ing. Cluster B included the established groupings of atrial fib-
rillation/flutter with cerebrovascular disease andwith thyroid
disease and diabetes with cerebrovascular disease. Another
recognised pairing was that of atrial fibrillation and cognitive
impairment found in Clusters B and E. Geriatric syndromes
tended to cluster together in line with previous reports [31,
32]. All five geriatric conditions occurred at higher than
average prevalence in Cluster B and three conditions in
Clusters D and E; in contrast, most geriatric conditions were
less prevalent in Cluster A. Geriatric syndromes are thought
to result from impairments across multiple systems; they
may share common risk factors and pathophysiological
mechanisms and could be amenable to unified intervention
strategies [19]. Of note, Clusters C, D, and E included less
familiar disease groupings, for example, ischaemic heart
disease, inflammatory arthritis, and osteoporosis (Cluster
C), and some diseases in Cluster A (asthma) and Cluster
B (inflammatory arthritis) do not readily “fit” with the rest
of the cluster. Disentangling the basis of such “unfamiliar”
associations may point the way to promising new avenues of
research [33].
Recent systematic reviews of studies of multimorbidity
patterns confirm the paucity of research in this area, par-
ticularly in the very old [33, 34]. Cluster analysis has been
used in a small number of studies [30, 35–41], many of
which focused on specific groups such as the hospitalised
elderly [37], Native Americans [38], US Veterans [39], and
homeless veterans [40]. Most studies used the approach of
clustering by condition rather than by participant [35–39,
41]; this produces somewhat crude groupings and has the
drawback that each condition can only appear in one cluster
(an artefact of the clustering algorithm [39]), as well as it
being less straightforward to assign study participants to
cluster groups and therefore to examine associations with
outcomes. Only two studies have, as we did, clustered by
participant to identify distinct subgroups of people sharing
similar morbidity profiles, neither of which used population-
based samples [30, 40].
Few studies have focused on the very old, all of which
used cluster analysis with clustering by condition.Marengoni
et al. examinedmorbidity patterns in the Kungsholmen study
(𝑛 = 1077, aged 77 and over) [36]; Formiga et al. in the
Octobaix study (𝑛 = 328 aged 85) [41]; and Dong et al. in
the ELSA 85 study (𝑛 = 496, aged 85) [35]. Five clusters
were identified in the Kungsholmen cohort: circulatory;
cardiopulmonary; dementia, depression and hip fracture;
diabetes and visual impairment; and cancer with anaemia
[36]. The Octobaix cohort had four main clusters: circula-
tory plus visual impairment; dementia, Parkinson’s disease,
peripheral vascular disease, dyslipidaemia, and anaemia;
chronic obstructive pulmonary disease and malignancy; and
hearing impairment [41]. Five main clusters were found in
women from the Elsa 85 cohort: vascular; cardiopulmonary;
dementia and affective disorders; osteoarthritis and urinary
incontinence; and malignancy and thyroid disease [35]. Our
study builds on these findings by including a larger sample
size of the very old and a larger number of conditions (with
osteoarthritis, incontinence and falls included) and by using
an alternative approach of clustering by participant rather
than by condition. Marked methodological heterogeneity
between studies makes direct comparison of the patterns
problematic; however the finding of circulatory cluster(s) is
a common theme across all studies of the very old, including
our own.
Studies ofmultimorbidity patterns, in all age groups, were
the focus of a recent systematic review by Prados-Torres et
al. [33]. Fourteen studies were included, 8 of which focused
on participants over 60 years whilst 3 included individuals
as young as 15; the Kungsholmen study was the only study
focusing on the very old [36]. Ninety-seven disease pat-
terns were identified across the 14 studies. The considerable
methodological variation between studies—in age group,
setting, number and types of conditions included, ascer-
tainment criteria, and statistical techniques—makes direct
comparison difficult. Nevertheless, three broad groups of
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patterns were highlighted: a cardiovascular/cardiometabolic
group, found in 10/14 studies; a mental health group, in
10/14 studies (at least one mental health problem, most
commonly depression and/or anxiety); and amusculoskeletal
group, in 10/14 studies (at least one musculoskeletal condi-
tion, most commonly arthropathy, back/neck pain, and/or
osteoporosis). In each of these broad groups, a wide range
of additional comorbidities was found, only some of which
had logical associations. Comparing these findings to studies
of the very old, all three broad groups can be seen in the
Elsa 85 cohort [35], two in the Kungsholmen cohort [36],
and one in the Octobaix cohort [41]. In the Newcastle 85+
cohort, our finding of a cardiometabolic cluster (Cluster A),
together with musculoskeletal conditions in Clusters C and
D, would fit with these broad trends, although we found
osteoarthritis to be of high prevalence in four of our five
clusters.Wewere unable to includemeasures ofmental health
in our analysis. Whilst it would be interesting to further
analyse pattern differences between the very old and younger
age groups, the marked methodological differences between
studies precludes meaningful interpretation.
Strengths of this study include its population-based
sample, which included the institutionalised and those with
cognitive impairment, and the domiciliary assessment which
avoids the selection bias inherent in clinic-based assessment
of this age group. The use of dual data sources is a further
strength; disease ascertainment frommedical records ismore
reliable than self-report in older age groups, particularly in
those challenged by multimorbidity or cognitive impairment
[42–44], whilst participant assessment is superior for geri-
atric conditions which may be undiagnosed and/or their
presence poorly documented [45]. Our work has a number of
limitations.The sample analysed (𝑛 = 710) represents 49% of
those eligible to participate. Within the limits of the analysis
possible, it does not appear that study nonparticipants were
less healthy than participants although those with cognitive
impairment may have been underrepresented [46]. However,
those participants excluded from the analysis due to missing
data were less healthy than those with complete data, and
consequently our data may underestimate the scale of multi-
morbidity. Some important conditions were excluded due to
absence in the study dataset or a high rate of missing values,
for example, mental health problems; hence our estimate
of multimorbidity is somewhat conservative. Our sample
derives from a single urban area in North East England, with
predominantly white ethnicity. Whilst 85-year-olds in this
area are sociodemographically and ethnically similar to those
in England and Wales as a whole [17], they may differ from
those in other parts of the world.
The extensive and complex morbidity burden found in
the majority of very old people presents a considerable chal-
lenge for healthcare services. Current approaches to chronic
disease management are focused largely on a single disease
paradigm. In patients with many conditions, application
of multiple disease-specific guidelines can lead to clinical
chaos, polypharmacy, and interactions between strategies for
individual conditions [47, 48]. Healthcare can become frag-
mented, costly, and potentially ineffective (or even injurious)
[9, 10]. Despite growing recognition of the importance of
multimorbidity, there remains insufficient data to inform
evidence-based care for multimorbid patients of any age [49]
and the knowledge gap is particularly acute in older people
[3]. Clinical trials routinely exclude patientswith cooccurring
conditions [50], and older people are consistently under-
represented [50, 51]. Clinical practice guidelines focused on
the index disease fail to address the needs of people with
complex multimorbidity [47, 48, 52]; furthermore they rarely
include information on the quality of research evidence in
older people or give specific recommendations for older
people [48, 53]. Strategies proposed to improve the care of
patients with multimorbidity [5–7, 54–58] will need to be
appropriate to the very old who, as we have shown, have
a considerable and complexmorbidity burden. In theUK, the
demarcations between (and within) primary care, commu-
nity health services, and secondary care and between health
and social care are increasingly seen as a barrier to providing
the personalised and coordinated approach needed by older
people with multimorbidity. The National Health Service is
therefore supporting the creation of major new models of
care integrated around the patient and their needs, which will
cross traditional organisational and departmental boundaries
[59].
5. Conclusions
Themajority of 85-year-olds in this population-based cohort
in North East England had extensive and complex morbidity.
The elaboration of clusters of older people sharing similar
morbidity profiles is likely, in time, to help throw light
on shared pathophysiological processes, creating the poten-
tial for novel preventive measures and targeted therapies.
Furthermore, it will inform the development of healthcare
services which are better able to meet the complex needs of
the very old.
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